# A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

> **NCT01340937** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 2808 (actual)

## Conditions studied

- Bacterial Infections
- Virus Diseases

## Interventions

- **BIOLOGICAL:** V419
- **BIOLOGICAL:** PENTACEL™
- **BIOLOGICAL:** Prevnar 13™
- **BIOLOGICAL:** RotaTeq™
- **BIOLOGICAL:** Recombivax HB vaccine

## Key facts

- **NCT ID:** NCT01340937
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-10
- **Primary completion:** 2012-12-18
- **Final completion:** 2013-07-26
- **Target enrollment:** 2808 (ACTUAL)
- **Last updated:** 2018-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01340937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01340937, "A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01340937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*